Growth hormone secretion in polytransfused prepubertal patients with homozygous β-thalassemia. Effect of long-term recombinant GH (recGH) therapy

Journal of Endocrinological Investigation

Volumn 26, Issue 7, 2003, Pages 623-628

  Masala, Antonio ^a   Atzeni, M M ^a   Alagna, S ^a   Gallisai, D ^b   Burrai, C ^b   Mela, M G ^b   Rovasio, P P ^a   Gallo, P ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Beta thalassemia; Ferritin; GH; Growth velocity; RecGH

Indexed keywords

CLONIDINE; DEFEROXAMINE; FERRITIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; IRON CHELATING AGENT; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; THYROXINE;

AGE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MATURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; GROWTH; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RATE; HOMOZYGOSITY; HUMAN; HYPOTHYROIDISM; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONITORING; PREPUBERTY; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE;

EID: 0142025217     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347019     Document Type: Article

References (29)

1. Danesi L, Scacchi M, De Martin M, et al. Evaluation of hypothalamic-pituitary function in patients with thalassemia major. J Endocrinol Invest 1992, 15: 177-84.
2. Masala A, Meloni T, Gallisai D, Alagna S, Rovasio PP, Rassu S. Endocrine functioning in multitransfused prepubertal patients with homozygous β-thalassemia. J Clin Endocrinol Metab 1984, 58: 667-70.
3. McIntosh N. Endocrinopathy in thalassemia major. Arch Dis Child 1976, 51: 195.
4. Italian Working Group on Endocrine Complications in Non-Endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol (Oxf) 1995, 42: 581-6.
5. Tiosano D, Hochberg Z. Endocrine complications of thalassemia. J Endocrinol Invest 2001, 24: 716-23.
6. Low LCK, Kwan EYW, Lim YJ, Lee ACW, Tam CF, Lam KSL. Growth hormone treatment of short chinese with β-thalassemia major without GH deficiency. Clin Endocrinol (Oxf) 1995, 42: 359-63.
7. Pintor C, Cella SG, Manso P, et al. Impaired growth hormone (GH) response to GH releasing hormone in thalassemia major. J Clin Endocrinol Metab 1986, 62: 263-7.
8. Katzos G, Harsoulis F, Papadopoulou M, Athanasiou M, Sava K. Circadian growth hormone secretion in short multitransfused prepubertal children with thalassemia major. Eur J Ped 1995, 154: 445-9.
9. Scacchi M, Danesi L, De Martin M, et al. Treatment with biosynthetic growth hormone of short thalassemic patients with impaired growth hormone secretion. Clin Endocrinol (Oxf) 1991, 35: 335-9.
10. Low LCK, Postel-Vinay MC, Kwan EYV, Cheung PT. Serum growth hormone (GH) binding protein, IGF-I and IGFBP-3 in patients with β-thalassemia major and the effect of GH treatment. Clin Endocrinol (Oxf) 1998, 48: 641-6.
11. Theodoridis C, Ladis V, Papatheodorou A, et al. Growth and management of short stature in thalassemia major. Pediatr Endocrinol Metab 1998, 11: 835-44.
12. Katzsos G, Papakostantinou-Athanasiadou E, Athanasiou-Metaxa M, Harsoulis F. Growth hormone treatment in short children with beta-thalassemia major. J Pediatr Endocrinol Metab 2000, 131: 163-70.
13. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 1976, 51: 170-9.
14. Vannasaeng S, Fucharoen S, Poutrakul P, Ploybutr S, Yansukon P. Pituitary function in thalassemic patients and the effect of chelation therapy. Acta Endocrinol (Copenh) 1991, 124; 23-30.
15. Vassillopoulou-Sellin R, Ojedeji CO, Foster PL, Thompson MM,Saman NA. Hemoglobin as a direct inhibitor of cartilage growth in vitro. Horm Metab Res 1989, 21: 11-4.
16. De Virgilis S, Congia M, Frau F, et al. Desferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988, 113: 661-9.
17. Cavallo L, Gurrado R, Gallo F, Zecchino C, De Mattia D, Tatò L. Growth deficiency in polytransfused β-thalassemia patients is not growth hormone dependent. Clin Endocrinol (Oxf) 1997, 46: 701-6.
18. Garcia-Major RV, Andrade Olivie A, Fernandez Catalina P, Castro M, Rego Iraeta A, Reparaz A. Linear growth in thalassemic children treated with intensive chelation therapy. A longitudinal study. Horm Res 1993, 40: 189-93.
19. Brill PV, Winchester P, Giardina PI, Cunningham-Rundles S. Desferrioxamine induced bone dysplasia in patients with thalassemia major. Am J Roentgenol 1991, 156: 561-5.
20. Naselli A, Vignolo M, Di Battista E, et al. Long-term follow-up of skeletal dysplasia in thalassemia major. J Pediatr Endocrinol Metab 1998, 11 (Suppl 3): 817-25.
21. Olivieri NF, Koren G, Harris J, et al. Growth failure and body changes induced by desferrioxamine. Am J Pediatr Hematol Oncol 1992, 14: 48-56.
22. De Sanctis V, Pinamonti A, Di Palma A., et al. Growth and development in thalssemia major patients with severe bone lesions due to desferroxamine. Eur J Pediatr 1996, 155: 368-72.
23. Cavallo L, Licci D, Acquafredda A, et al. Endocrine involvement in children with β-thalassemia major. Transversal and longitudinal studies. I. Pituitary-thyroidal axis function and is correlation with serum ferritin levels. Acta Endocrinol (Copenh) 1984, 107: 49-53.
24. Frasier SD. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr Rev 1983, 4: 155-70.
25. Chrysis DC, Alexandrides TK, Koromantzou E, et al. Novel application of IGF-I and IGFBP-3 generation tests in the diagnosis of growth hormone axis disturbances in children with β-thalassemia. Clin Endocrinol (Oxf) 2001, 54: 253-9.
26. Masala A, Meloni T, Alagna S, et al. Plasma growth hormone (GH) and somatomedin-C (SM-C) levels in patients with homozygous β-thalassemia. Exp Clin Endocrinol 1988, 7: 161-3.
27. Masala A, Meloni T, Gallisai D, et al. The effects of thyrotropin releasing hormone and luteinizing hormone releasing hormone on growth hormone release in patients with homozygous β-thalassemia. J Clin Endocrinol Metab 1982, 54: 1271-74.
28. Masala A, Alagna S, Faedda R, et al. Paradoxical growth hormone (GH) release in response to thyrotropin releasing hormone (TRH) in patients with Wilson's disease. J Nucl Med All Sci 1987, 31: 104-5.
29. Berkovitch M, Bistritzer T, Milone SD, Perlman K, Kucharczyk W, Olivieri NF. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. J Pediatr Endocrinol Metab 2000, 13: 179-84.